Market Place
Sourcing Support
Telitacicept Hits Primary Endpoint In Ph3 IgA Nephropathy Study
08 Nov 2025 //
GLOBENEWSWIRE
Telitacicept Shows Long-Term Efficacy In 48-Week China Ph 3 Data
29 Oct 2025 //
GLOBENEWSWIRE
Vor Bio to Host Webcast on China Ph3 Telitacicept Sjögren’s Data
22 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Presents China Phase 3 Iga Nephropathy Study At ASN
17 Oct 2025 //
GLOBENEWSWIRE
Vor Bio Publishes China Phase 3 Telitacicept Study In Lupus
16 Oct 2025 //
GLOBENEWSWIRE
Telitacicept Show Significant ESSDAI Impact in China Ph3 ACR 2025
14 Oct 2025 //
GLOBENEWSWIRE
Telitacicept Phase III Data In Sjögren`s Syndrome At 2025 ACR
14 Oct 2025 //
PR NEWSWIRE
Vor Bio Presents Phase 3 Sjögren`s Disease Study Poster At ACR
29 Sep 2025 //
GLOBENEWSWIRE
Vor Bio Presents 48-Week China Ph 3 Myasthenia Gravis Study
17 Sep 2025 //
GLOBENEWSWIRE
RemeGen`s Telitacicept Result sets up IgAN Submission in China
28 Aug 2025 //
FIERCE PHARMA
Telitacicept Ph III Succeeds in Primary Sjögren’s Syndrome
13 Aug 2025 //
PR NEWSWIRE
Telitacicept Hits Phase 3 Goal in Primary Sjögren`s Disease Study
13 Aug 2025 //
GLOBENEWSWIRE
RemeGen`s Telitacicept (RC18) Received Orphan Drug Designation
17 Jun 2025 //
PR NEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.